We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

GlaxoSmithKline Consumer Healthcare (Ireland) Ltd

12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
E-mail: customer.relations@gsk.com
Medical Information Direct Line: 1800 441 442

Summary of Product Characteristics last updated on medicines.ie: 10/07/2015
SPC Panadol Sinus Relief Film Coated Tablets

Go to top of the page

Panadol Sinus Relief Film Coated Tablets

Paracetamol 500mg

Caffeine 25mg

Phenylephrine Hydrochloride 5mg

Go to top of the page

Each film coated tablet contains paracetamol 500 mg, caffeine 25 mg and phenylephrine hydrochloride 5 mg.

Excipients: also includes sunset yellow (E110), 0.5935 mg per tablet.

For a full list of excipients, see section 6.1.

Go to top of the page

Film-coated tablet

Orange film-coated tablet embossed with 'B' on one side.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

The product is recommended for the relief of the symptoms of nasal and sinus congestion, colds and flus.

Go to top of the page
4.2 Posology and method of administration

Oral administration only.

Do not exceed the stated dose.

Should not be used with other paracetamol-containing products, decongestants, or cold and flu medicines.

Adults (including the elderly) and children aged 12 years and over :

One to two tablets up to four times a day.

Maximum daily dose: Eight tablets in 24 hours.

Minimum dosing interval: 4 hours

Maximum duration of continued use without medical advice: 3 days.

Not recommended for children under 12 years of age.

Go to top of the page
4.3 Contraindications

Known hypersensitivity to paracetamol, phenylephrine, caffeine or any of the other ingredients listed in section 6.1.

Use in children under 12 years of age.

Severe hepatic or severe renal impairment, hypertension, hyperthyroidism, diabetes, closed angle glaucoma, phaeochomocytoma, prostate hypertrophy and heart disease. Patients taking tricyclic antidepressants, or beta-blocking drugs and those who are taking or who have taken within the last two weeks monoamine oxidase inhibitors.

Go to top of the page
4.4 Special warnings and precautions for use

Care is advised in the administration of paracetamol to patients with renal or hepatic impairment. Underlying liver disease increases the risk of paracetamol-related liver damage. The hazard of overdose is greater in those with non- cirrhotic alcoholic liver disease.

Do not exceed the stated dose.

Patients should be advised not to take other paracetamol-containing products concurrently.

Medical advice should be sought before using this product in patients with occlusive vascular disease (e.g. Raynaud's phenomenon).

This product should not be used by patients taking other sympathomimetics (such as decongestants, appetite suppressants and amphetamine-like psychostimulants).

Excessive intake of caffeine (e.g. coffee, tea and some canned drinks) should be avoided while taking this product.

If symptoms persist consult your doctor.

Keep out of the reach and sight of children.

Consult your doctor if you are taking warfarin or have been diagnosed with liver or kidney disease.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Medical advice should be sought before taking paracetamol-caffeine-phenylephrine in combination with the following drugs:

Monoamine oxidase inhibitors

Hypertensive interactions occur between sympathomimetic amines such as phenylephrine and monoamine oxidase inhibitors.

Sympathomimetic amines

Concomitant use of phenylephrine with other sympathomimetic amines can increase the risk of cardiovascular side effects.

Beta-blockers, and other antihypertensives (including debrisoquine, guanethidine, reserpine, methyldopa)

Phenylephrine may reduce the efficacy of beta- blocking drugs and hypertensive drugs. The risk of hypertension and other cardiovascular side effects may be increased.

Tricyclic antidepressants (e.g, amitriptyline)

May increase the risk of cardiovascular side effects with phenylephrine.

Digoxin and cardiac glycosides

Concomitant use of phenylephrine with digoxin or cardiac glycosides may increase the risk of irregular heartbeat or heart attack.

Warfarin and other coumarins

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.

The speed of absorption of paracetamol may be increased by metoclopramide and domperidone and reduced by cholestyramine, however, these interactions are not considered to be clinically significant in over-the-counter paracetamol-containing products which are intended for short term usage.

Enzyme-inducing drugs may increase hepatic damage, as does excessive intake of alcohol.

4.6 Fertility, pregnancy and lactation


This product is not recommended for use during pregnancy.


Human and animal studies with paracetamol have not identified any risk to paracetamol in pregnancy or embryo-foetal development.


This product is not recommended for use during pregnancy due to the possible increased risk of spontaneous abortion associated with caffeine consumption.


No relevant data available.


This product should not be used while breast-feeding without medical advice.


Human studies with paracetamol at the recommended doses have not identified any risk to lactation or the breast-fed offspring.


Caffeine in the breast milk may potentially have a stimulating effect on breast-fed infants but significant toxicity has not been observed.


Phenylephrine may be excreted in breast milk. The drug should not be used while breast-feeding without medical advice.

Go to top of the page
4.7 Effects on ability to drive and use machines

Patients should be advised not to drive or operate machinery if affected by dizziness.

Go to top of the page
4.8 Undesirable effects


Adverse events from historical clinical trial data are both infrequent and from small patient exposure.

Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by MedDRA System Organ Class. As these reactions are reported voluntarily from a population of uncertain size, the frequency of these reactions is unknown but considered likely to be very rare (<1/10,000).

Body System

Undesirable effect

Blood and lymphatic system disorders


Immune System disorders


Cutaneous hypersensitivity reactions, including skin rashes, angioedema and Stevens Johnson syndrome.

Respiratory, thoracic and mediastinal disorders

Bronchospasm in patients sensitive to aspirin and other non-steroidal anti-inflammatory drugs


Hepatic dysfunction


Adverse reactions identified through post-marketing use with caffeine are listed below.

The frequency of these reactions is unknown.

Central Nervous System



When the recommended paracetamol-caffeine dosing regimen is combined with dietary caffeine intake, the resulting higher dose of caffeine may increase the potential for caffeine-related adverse effects such as insomnia, restlessness, anxiety, irritability, headaches, gastrointestinal disturbances and palpitations.


The following adverse events have been observed in clinical trials with phenylephrine and may therefore represent the most commonly occurring adverse events. Adverse events are listed below by MedDRA System Organ Class:

Body System

Undesirable Effect

Psychiatric disorders


Nervous System disorders

Headache, dizziness, insomnia

Cardiac disorders

Increased blood pressure

Gastrointestinal disorders

Nausea, vomiting

Adverse reactions identified during post-marketing use are listed below. The frequency of these reactions is unknown but likely to be rare (<1/1000).

Eye disorders

Mydriasis, acute angle closure glaucoma, most likely to occur in those with closed angle glaucoma

Cardiac disorders

Tachycardia, palpitations

Skin and subcutaneous disorders

Allergic reactions (e.g. rash, urticaria, allergic dermatitis)

Renal and urinary disorders

Dysuria, urinary retention. This is most likely to occur in those with bladder outlet obstruction, such as prostatic hypertrophy

Go to top of the page
4.9 Overdose


Paracetamol overdose may cause liver failure. Some patients may be at increased risk of liver damage from paracetamol toxicity.

Risk factors include:

If the patient

a, Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.


b, Regularly consumes ethanol in excess of recommended amounts.


c, Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms and sings

Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.


Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines.

Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with the National Poisons Information Service or a liver unit.


Symptoms and signs

Phenylephrine overdosage is likely to result in effects similar to those listed under adverse reactions. Additional symptoms may include irritability, restlessness, hypertension, and possibly reflex bradycardia. In severe cases confusion, hallucinations, seizures and arrhythmias may occur. However the amount required to produce serious phenylephrine toxicity would be greater than required to cause paracetamol-related liver toxicity.


Treatment should be clinically appropriate. Severe hypertension may need to be treated with alpha blocking drug such as phentolamine.


Symptoms and signs

Overdose of caffeine may result in epigastric pain, vomiting, diuresis, tachycardia or cardiac arrhythmia, CNS stimulation (insomnia, restlessness, excitement, agitation, jitteriness, tremors and convulsions).

It must be noted that for clinically significant symptoms of caffeine overdose to occur with this product, the amount ingested would be associated with serious paracetamol-related liver toxicity.


No specific antidote is available, but supportive measures may be used.


Treatment of overdose requires assessment of plasma paracetamol levels for antidote treatment, with signs and symptoms of caffeine toxicity being managed symptomatically.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

ATC Code: N02BE51

Paracetamol is a well established analgesic and antipyretic. Its mechanism of action is believed to include inhibition of prostaglandin synthesis, primarily within the central nervous system.

Phenylephrine hydrochloride is a sympathomimetic agent with mainly direct effects on adrenergic receptors (predominantly alpha-adrenergic activity) producing nasal decongestion.

Caffeine is the most active xanthine derivative in respect of stimulation of the central nervous system, producing a condition of wakefulness and increased mental activity.

Go to top of the page
5.2 Pharmacokinetic properties

Paracetamol is metabolised by the hepatic microsomal enzymes. It is rapidly and completely absorbed from the gastro- intestinal tract. Plasma concentration reaches a peak in half to one hour, the plasma half-life is one to three hours and it is uniformly distributed throughout the body.

Phenylephrine hydrochloride is irregular absorbed from the gastro-intestinal tract. When injected intramuscularly it takes 10-15 minutes to act and subcutaneous and intramuscular injections are effective for about one hour. Intravenous injections are effective for about 20 minutes.

Caffeine is readily absorbed from the gastro-intestinal tract.

Go to top of the page
5.3 Preclinical safety data

Not applicable.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Maize starch

Pregelatinised Starch


Potassium sorbate

Sodium laurilsulfate

Eurocol sunset yellow (E110)

Stearic acid


Microcrystalline cellulose

Film coating

Hypromellose 6cps

Macrogol 400

Titanium dioxide (E171)

Sunset yellow aluminium lake (E110)

Quinoline yellow lake (E104)

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

2 years.

Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Store in the original container in order to protect from moisture.

Go to top of the page
6.5 Nature and contents of container

White, opaque PVC aluminium foil blisters in boxes. Pack sizes are 10, 12, 16, 20, 24, 40 and 48 tablets. Not all pack sizes may be marketed.

Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Go to top of the page

GlaxoSmithKline Consumer Healthcare (Ireland) Limited,

12 Riverwalk,

Citywest Business Campus,

Dublin 24,


Go to top of the page

PA 678/44/1

Go to top of the page

Date of first authorisation: 20 August 1992

Date of last renewal: 20 August 2007

Go to top of the page

July 2015

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

   Phenylephrine Hydrochloride